ContraFect Corp (CFRX)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

28 WELLS AVENUE YONKERS, NY 10701

ContraFect is a biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. The Company intends to address life threatening infections using its therapeutic product candidates from its platform of DLAs, which include lysins and amurin peptides. Lysins are a new class of DLAs which are recombinantly produced antimicrobial proteins with a novel mechani® of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. Amurin peptides are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including P. aeruginosa, Acinetobacter baumannii, and Enterobacter species. The Comapny believes that the properties of its lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. It has completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis, with its lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S. Exebacase, currently being studied in a pivotal Phase 3 clinical study, was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to SOC anti-staphylococcal antibiotics in adult patients.

Data as of 2021-09-26 20:44:11 -0400
Market Cap157.724 Million Shares Outstanding39.333 Million Avg 30-day Volume123.962 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS0
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE-4.33 Enterprise Value
Total Cash Current Debt Gross Profit
BETA1.46866 52-week High/Low7.63 / 3.1 Next Earnings Date2021-11-12 Price to Cash FLow (P/CF) -32.0467
Data provided by IEX Cloud
View SEC Filings from CFRX instead.

View recent insider trading info

Funds Holding CFRX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CFRX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BARER SOL J

  • Director
25,000 2021-05-18 1

OTTO MICHAEL J.

  • Director
25,000 2021-05-18 1

GILMAN STEVEN C

  • Director
25,000 2021-05-18 1

SUCOFF CARY

  • Director
25,000 2021-05-18 1

LOW DAVID N.

  • Director
25,000 2021-05-18 1

AKLOG LISHAN

  • Director
25,000 2021-05-18 1

POMERANTZ ROGER CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
254,000 2021-04-08 1

MESSINGER MICHAEL CHIEF FINANCIAL OFFICER

  • Officer
80,000 2021-04-08 1

BOGDANOS NATALIE GENERAL COUNSEL

  • Officer
70,000 2021-04-08 1

CASSINO CARA M CHIEF MEDICAL OFFICER

  • Officer
170,000 2021-04-08 1

BARLOW JANE F

  • Director
0 2021-02-08 2

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
CONTRAFECT CORP CFRX 2021-09-27 22:15:03 UTC -0.5416 0.6116 800000
CONTRAFECT CORP CFRX 2021-09-27 21:45:03 UTC -0.5416 0.6116 800000
CONTRAFECT CORP CFRX 2021-09-27 21:15:03 UTC -0.5416 0.6116 800000
CONTRAFECT CORP CFRX 2021-09-27 20:45:04 UTC -0.5416 0.6116 800000
CONTRAFECT CORP CFRX 2021-09-27 20:15:03 UTC -0.5416 0.6116 800000
CONTRAFECT CORP CFRX 2021-09-27 19:45:03 UTC -0.5416 0.6116 800000
CONTRAFECT CORP CFRX 2021-09-27 19:15:03 UTC -0.5416 0.6116 800000
CONTRAFECT CORP CFRX 2021-09-27 18:45:02 UTC -0.5416 0.6116 800000
CONTRAFECT CORP CFRX 2021-09-27 18:15:03 UTC -0.5416 0.6116 800000
CONTRAFECT CORP CFRX 2021-09-27 17:45:03 UTC -0.5416 0.6116 800000
CONTRAFECT CORP CFRX 2021-09-27 17:15:04 UTC -0.5416 0.6116 800000
CONTRAFECT CORP CFRX 2021-09-27 16:45:03 UTC -0.5416 0.6116 800000
CONTRAFECT CORP CFRX 2021-09-27 16:15:03 UTC -0.5416 0.6116 800000
CONTRAFECT CORP CFRX 2021-09-27 15:45:03 UTC -0.5416 0.6116 800000
CONTRAFECT CORP CFRX 2021-09-27 15:15:03 UTC -0.5416 0.6116 800000
CONTRAFECT CORP CFRX 2021-09-27 14:45:02 UTC -0.7034 0.7734 800000
CONTRAFECT CORP CFRX 2021-09-27 14:15:03 UTC -0.7034 0.7734 800000
CONTRAFECT CORP CFRX 2021-09-27 13:45:03 UTC -0.7034 0.7734 800000
CONTRAFECT CORP CFRX 2021-09-27 13:15:03 UTC -0.7034 0.7734 800000
CONTRAFECT CORP CFRX 2021-09-27 12:45:04 UTC -0.7034 0.7734 800000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments